Amy Mosman, PA
Medical · Saint Louis, MONPI 1255756961
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (35.4%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Ardelyx, Inc. accounts for 77.3% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $14,027, more than ten times the $50 reported in 2021. Among medical clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 97 payments — averaging $221.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ardelyx, Inc.$17K
- Novo Nordisk$1K
- Medtronic$1K
- Amgen$390
- Bayer$246
- Scpharmaceuticals Inc.$219
- plus $2K from 18 others
What the payments were for
- Consulting fees$3,11514%
- Speaking & faculty fees$7,60035%
- Travel & lodging$5,70127%
- Food & beverage$5,05824%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ardelyx, Inc. | 51 | $16,621 |
| Novo Nordisk | 5 | $1,449 |
| Medtronic | 11 | $1,051 |
| Amgen | 3 | $390 |
| Bayer | 2 | $246 |
| Scpharmaceuticals Inc. | 2 | $219 |
| AstraZeneca | 2 | $205 |
| Janssen Scientific Affairs, LLC | 2 | $159 |
| Madrigal Pharmaceuticals | 1 | $129 |
| Exact Sciences | 1 | $125 |
| GSK | 2 | $122 |
| Corcept Therapeutics | 1 | $106 |
| Vifor Pharma, Inc. | 1 | $98 |
| Phathom Pharmaceuticals, Inc. | 1 | $97 |
| Convatec Inc. | 1 | $96 |
| Vertex | 1 | $92 |
| AbbVie | 1 | $91 |
| Travere Therapeutics, Inc. | 2 | $44 |
| Cormedix Inc. | 1 | $36 |
| Nxstage Medical, Inc. | 2 | $34 |
| Akebia Therapeutics Inc | 1 | $24 |
| Calliditas Therapeutics US Inc. | 1 | $22 |
| Fresenius USA Marketing, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XPHOZAH 30 MG$15,244
- ELLIPSYS VASCULAR ACCESS SYSTEM$793
- Repatha$269
- Kerendia$246
- REZDIFFRA$129
- FUROSCIX$126
- Cologuard Collection Kit$125
- FARXIGA$125
- Korlym$106
- COREVALVE EVOLUT R$104
- BLUJEPA$104
How this compares
$21,493 in reported general payments places this provider in the 95th percentile of 198 medical providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuryxiaFerric Citrate | 87 | $190,602 |
| XphozahTenapanor Hcl | 34 | $119,597 |
| VelphoroSucroferric Oxyhydroxide | 20 | $51,468 |
| JardianceEmpagliflozin | 37 | $36,498 |
| OzempicSemaglutide | 24 | $34,378 |
| EliquisApixaban | 30 | $30,000 |
| FarxigaDapagliflozin Propanediol | 33 | $28,345 |
| VeltassaPatiromer Calcium Sorbitex | 32 | $26,641 |
| KerendiaFinerenone | 13 | $23,700 |
| Sevelamer Carbonate | 44 | $8,974 |
| Calcium Acetate | 54 | $4,636 |
| Midodrine Hcl | 45 | $2,378 |
| Calcitriol | 58 | $1,033 |
| Torsemide | 50 | $836 |
| Bumetanide | 20 | $758 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Akebia Therapeutics IncAuryxia | $24 | $190,60287 claims |
| Fresenius USA Marketing, Inc.Velphoro | $20 | $51,46820 claims |
| Boehringer IngelheimJardiance | $19 | $36,49837 claims |
| Novo NordiskOzempic | $1,449 | $34,37824 claims |
| AstraZenecaFarxiga | $205 | $28,34533 claims |
| BayerKerendia | $246 | $23,70013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 198 medical providers in Missouri.
Other medical in Saint Louis
- Alexa Fider-WhyteSaint Louis$18K
- Megan Isaacson-SchmidSaint Louis$16K
- Erin YoffieSaint Louis$16K
- Beatrice BernhartSaint Louis$15K
- Lindsay ExlineSaint Louis$8K
- Mustafa AhmedSaint Louis$8K
- Elizabeth HowardSaint Louis$4K
- Macara JacobsSaint Louis$4K
- Kayla BergmannSaint Louis$4K
- David VanhoornbeekSaint Louis$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.